Armistice Capital LLC bought a new stake in Assembly Biosciences, Inc. (NASDAQ:ASMB - Free Report) in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor bought 468,000 shares of the biopharmaceutical company's stock, valued at approximately $6,421,000. Armistice Capital LLC owned about 8.49% of Assembly Biosciences at the end of the most recent reporting period.
Separately, Acadian Asset Management LLC grew its position in Assembly Biosciences by 131.0% in the 2nd quarter. Acadian Asset Management LLC now owns 13,558 shares of the biopharmaceutical company's stock worth $184,000 after purchasing an additional 7,690 shares in the last quarter. 19.92% of the stock is currently owned by hedge funds and other institutional investors.
Assembly Biosciences Stock Performance
NASDAQ ASMB traded up $0.21 during trading hours on Thursday, reaching $15.55. 37,534 shares of the company were exchanged, compared to its average volume of 23,203. Assembly Biosciences, Inc. has a 1 year low of $7.69 and a 1 year high of $20.04. The business's 50 day simple moving average is $15.52 and its 200-day simple moving average is $14.52.
Assembly Biosciences (NASDAQ:ASMB - Get Free Report) last issued its quarterly earnings results on Thursday, August 8th. The biopharmaceutical company reported ($1.98) earnings per share (EPS) for the quarter, topping the consensus estimate of ($2.96) by $0.98. The company had revenue of $8.53 million for the quarter, compared to analysts' expectations of $5.96 million. On average, research analysts predict that Assembly Biosciences, Inc. will post -7.82 EPS for the current year.
Insiders Place Their Bets
In other news, major shareholder Alexander Schornstein acquired 4,438 shares of the stock in a transaction that occurred on Friday, July 5th. The shares were acquired at an average cost of $12.52 per share, for a total transaction of $55,563.76. Following the purchase, the insider now owns 693,113 shares of the company's stock, valued at approximately $8,677,774.76. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Company insiders own 5.10% of the company's stock.
Analyst Ratings Changes
ASMB has been the topic of several recent analyst reports. Jefferies Financial Group raised shares of Assembly Biosciences from a "hold" rating to a "buy" rating and lifted their target price for the stock from $2.00 to $35.00 in a research report on Friday, September 20th. HC Wainwright reissued a "neutral" rating on shares of Assembly Biosciences in a research report on Tuesday.
Read Our Latest Analysis on Assembly Biosciences
About Assembly Biosciences
(
Free Report)
Assembly Biosciences, Inc, a biotechnology company, develops therapeutic candidates for the treatment of viral diseases. It develops ABI-5366, a long-acting herpes simplex virus (HSV) helicase-primase inhibitor that is in Phase 1a/1b clinical trial to treat recurrent genital herpes; ABI-1179, which is in Phase 1a/1b clinical trial for the treatment of recurrent genital herpes; and ABI-6250, a small molecule orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical trial.
Featured Articles
Before you consider Assembly Biosciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Assembly Biosciences wasn't on the list.
While Assembly Biosciences currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
